Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-tumor medicine composition and purpose thereof

A technology of antineoplastic drugs and compositions, applied in the field of pharmaceutical compositions containing arctigenin and nitrosourea alkylating agents, and the field of antineoplastic drug compositions, which can solve the problems of high treatment cost, long drug effect time, and large side effects To achieve obvious synergistic effects, clear ingredients, and reduce toxic and side effects

Active Publication Date: 2014-07-23
SHANDONG NEWTIME PHARMA
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] In order to solve the shortcomings of existing tumor therapeutic drugs in clinical application, especially the defects of large side effects and high treatment cost in most current tumor therapeutic drugs, the present invention provides a drug with long drug effect time, low price and less side effects combination

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-tumor medicine composition and purpose thereof
  • Anti-tumor medicine composition and purpose thereof
  • Anti-tumor medicine composition and purpose thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0060] Example 1 Preparation of arctigenin and carmustine composition microemulsion preparation

[0061] Table 2 Microemulsion preparation of arctigenin and carmustine composition

[0062]

[0063] Preparation process: Weigh 30 mg of caprylic acid glyceride and 50 mg of emulsifier OP, add them to 20 mg of propylene glycol, and mix well to obtain a suspension solution. Accurately weigh 25mg arctigenin and 2.5mg carmustine, respectively add them to the suspension solution, and ultrasonically dissolve arctigenin and carmustine to obtain a microemulsion of the combination of arctigenin and carmustine Concentrate. The microemulsion concentrate obtained above is diluted with water in a weight ratio of 1:10-20 to a clear solution to obtain microemulsion.

Embodiment 2

[0064] Example 2 Preparation of arctigenin and lomustine combination tablets

[0065] Table 3 Tablets of arctigenin and lomustine composition

[0066]

[0067] Preparation process: pass the arctigenin and lomustine through 80 mesh sieve, weigh according to the prescription, mix well, then mix with hydroxypropyl cyclodextrin in equal increments, pass through 60 mesh sieve, and then with The remaining auxiliary materials of the prescription amount are mixed uniformly, the content of the semi-finished product is measured, the tablet weight is calculated, and the tablet is compressed, and it is obtained.

Embodiment 3

[0068] Example 3 Preparation of microemulsion preparation of arctigenin and carmustine composition

[0069] Table 4 Microemulsion preparation of arctigenin and carmustine composition

[0070]

[0071]

[0072] Preparation process: Weigh the prescription amount of medium-chain fatty acid glycerides, polyoxyethylene castor oil EL-40, 1,2-propylene glycol, and absolute ethanol, mix them and stir them evenly, then add arctigenin and carmustine to dissolve them. Ultrasonic treatment can be used to accelerate the dissolution to obtain a clear concentrate, which is the arctigenin microemulsion concentrate. The microemulsion concentrate obtained above is diluted with water in a weight ratio of 1:10-20 to a clear solution to obtain microemulsion.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a solid tumor resisting medicine composition with arctigenin and nitrosourea alkylating agent anti-tumor medicines as active components. The weight ratio of arctigenin to nitrosourea alkylating agent anti-tumor medicines is 1:0.001-1000, and preferably 1:0.01-600. The anti-tumor medicine composition provided by the invention is advantaged in clear components, wide anti-tumor spectrum, substantial treatment effect against various tumors, low price, low side-effects, and good clinical application prospect.

Description

Technical field [0001] The invention relates to an anti-tumor pharmaceutical composition and its use, in particular to a pharmaceutical composition containing arctigenin and a nitrosourea alkylating agent and its anti-solid tumor use, belonging to the technical field of medicines. Background technique [0002] Alkylating agents are a type of anti-tumor drugs commonly used clinically, and are chemical substances that can transfer small hydrocarbon groups to other molecules. The common feature of alkylating agents is that they have one or more highly active alkylating groups, which can combine with cell proteins and nucleic acids in the body, so that proteins and nucleic acids lose their normal physiological activities, thereby harming cells and inhibiting cancer cell division . Alkylating agents are cell cycle non-specific drugs and generally have a strong killing effect on cells in M ​​and G1 phases. Small doses can inhibit cells from S phase to M phase. Cells in G2 phase are ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/00A61K31/365A61P35/02
Inventor 赵志全王洪臣
Owner SHANDONG NEWTIME PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com